{
  "oags": "0.2",
  "status": "alpha",
  "entry": {
    "id": "IB-arxiv-2604.09369-crossabsense-gdp-a1",
    "type": "evidence",
    "claim": "On the GDPa1 benchmark of 242 therapeutic IgGs, CrossAbSense improved 12–20% over established baselines on three of five developability assays.",
    "evidence_grade": "E3",
    "state": "active",
    "primary_source_ref": [
      {
        "kind": "arxiv",
        "id": "2604.09369",
        "version": "v1",
        "url": "https://arxiv.org/abs/2604.09369",
        "locator": "abstract"
      }
    ],
    "quantities": {
      "n_iggs": 242,
      "n_assays": 5,
      "n_improved_assays": 3,
      "gain_pct_low": 12,
      "gain_pct_high": 20
    },
    "declared_loss": null,
    "source_title": "Biologically-Grounded Multi-Encoder Architectures as Developability Oracles for Antibody Design",
    "authors": [
      "Simon J. Crouzet"
    ],
    "result_origin": "measured",
    "support_quote": "On the GDPa1 benchmark of 242 therapeutic IgGs, our oracles achieve notable improvements of 12--20\\% over established baselines on three of five developability assays",
    "source_version": "v1",
    "abstract_check": {
      "version": "v1",
      "date": "2026-10-08",
      "quote_verbatim": true
    },
    "domain_v2": "q-bio/biomolecules"
  },
  "expand": [],
  "incoming": [],
  "links": [],
  "declared_losses": [
    "Public evidence-graph projection: internal analytic/theory edges and private provenance are withheld by design.",
    "Alpha: some primary-source refs await precise citation verification."
  ],
  "generated": "2026-10-08"
}